Breast Cancer Res Treat

• 

  Publication Venue For

  • Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..  176:321-328. 2019
  • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)..  176:303-310. 2019
  • Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer..  176:445-451. 2019
  • Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence..  174:413-422. 2019
  • Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype..  174:209-218. 2019
  • Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set..  173:455-463. 2019
  • Obesity and mortality after locoregional breast cancer diagnosis..  172:647-657. 2018
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival..  172:123-132. 2018
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study..  171:325-334. 2018
  • Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer..  171:111-120. 2018
  • Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions..  170:593-603. 2018
  • Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011..  170:361-371. 2018
  • Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)..  166:793-808. 2017
  • Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer..  166:241-247. 2017
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)..  165:677-686. 2017
  • Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers..  165:247-260. 2017
  • Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications..  164:745. 2017
  • Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications..  164:263-284. 2017
  • Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?.  164:253-262. 2017
  • Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)..  164:107-117. 2017
  • Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)..  163:391-398. 2017
  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral..  162:275-282. 2017
  • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset..  162:1-10. 2017
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)..  161:363-373. 2017
  • Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors..  159:535-543. 2016
  • Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion..  158:441-454. 2016
  • Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources..  157:575-586. 2016
  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS)..  157:447-459. 2016
  • Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer..  156:351-359. 2016
  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer..  154:563-571. 2015
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor..  154:287-297. 2015
  • Breast cancer survival in African-American women by hormone receptor subtypes..  153:211-218. 2015
  • Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing..  153:191-200. 2015
  • Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer..  152:347-356. 2015
  • Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer..  152:163-172. 2015
  • Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)..  152:77-85. 2015
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)..  151:589-596. 2015
  • Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population..  151:465-474. 2015
  • A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007..  148:99-106. 2014
  • Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study..  147:415-421. 2014
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases..  146:557-566. 2014
  • Breast cancer and aging: results of the U13 conference breast cancer panel..  146:1-6. 2014
  • Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers..  146:421-427. 2014
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer..  146:199-209. 2014
  • Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families..  145:625-634. 2014
  • Long-term risk of medical conditions associated with breast cancer treatment..  145:233-243. 2014
  • Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy..  143:531-539. 2014
  • Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women..  141:261-268. 2013
  • A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting..  139:863-872. 2013
  • Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907..  139:607-616. 2013
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast..  139:381-390. 2013
  • Prevalence and impact of correlative science in breast cancer phase II trials..  139:845-850. 2013
  • The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study..  138:909-916. 2013
  • A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer..  137:471-482. 2013
  • Impact of breast cancer on anti-mullerian hormone levels in young women..  137:571-577. 2013
  • Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism..  137:359-371. 2013
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer..  136:35-43. 2012
  • The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors..  136:9-20. 2012
  • Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer..  134:371-378. 2012
  • Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice..  133:301-310. 2012
  • Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study..  132:1147-1155. 2012
  • Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways..  132:487-498. 2012
  • ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells..  132:109-119. 2012
  • Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients..  130:255-266. 2011
  • Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger..  130:587-597. 2011
  • Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life..  130:243-254. 2011
  • What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?.  130:691-697. 2011
  • The effect of system-level access factors on receipt of reconstruction among Latina and white women with DCIS..  129:909-917. 2011
  • Surgery of the primary tumor does not improve survival in stage IV breast cancer..  129:459-465. 2011
  • Characterizing the impact of 25 years of DCIS treatment..  129:165-173. 2011
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms..  128:483-493. 2011
  • Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer..  127:511-520. 2011
  • Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women..  127:479-487. 2011
  • The role of polymorphisms in circadian pathway genes in breast tumorigenesis..  127:531-540. 2011
  • Individual responses to chemotherapy-induced oxidative stress..  125:583-589. 2011
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue..  124:297-305. 2010
  • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis..  124:441-451. 2010
  • Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families..  123:581-585. 2010
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer..  122:135-144. 2010
  • The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger..  122:243-249. 2010
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer..  121:771-776. 2010
  • A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer..  120:111-118. 2010
  • Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2..  119:409-414. 2010
  • Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer..  119:137-144. 2010
  • Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care..  118:635-643. 2009
  • Reporting of race and ethnicity in breast cancer research: room for improvement..  118:511-517. 2009
  • Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells..  118:197-205. 2009
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants..  115:123-129. 2009
  • Analysis of dermatologic events in patients with cancer treated with lapatinib..  114:485-493. 2009
  • Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women..  114:327-338. 2009
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)..  113:479-490. 2009
  • Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program..  113:189-196. 2009
  • Are all aromatase inhibitors alike?.  112 Suppl 1:35-43. 2008
  • Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged .  110:357-366. 2008
  • EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor..  107:235-242. 2008